Skip to main content

Replimune Group Inc

For the period ended Dec 31, 2023. Filed Feb 8, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Dec 31, 2023 · Filed Feb 8, 2024

REPL$22.26+3.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations

(Amounts in thousands, except share and per share amounts)

Three Months Ended December 31,Nine Months Ended December 31,
2023202220232022
Operating expenses:
Research and development$42,847$30,261$132,384$88,573
Selling, general and administrative13,69311,36943,63335,512
Total operating expenses56,54041,630176,017124,085
Loss from operations(56,540)(41,630)(176,017)(124,085)
Other income (expense):
Research and development incentives4156071,2512,032
Investment income5,6862,67517,9224,130
Interest expense on finance lease liability(540)(548)(1,626)(1,650)
Interest expense on debt obligations(1,012)(941)(3,083)(941)
Other income (expense)1,3441471,307(4,531)
Total other income (expense), net5,8931,94015,771(960)
Loss before income taxes$(50,647)$(39,690)$(160,246)$(125,045)
Income tax provision473$—$473$—
Net loss$(51,120)$(39,690)$(160,719)$(125,045)
Net loss per common share, basic and diluted$(0.77)$(0.69)$(2.42)$(2.25)
Weighted average common shares outstanding, basic and diluted66,645,69157,857,13266,532,48855,618,052
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.